Research
Hormonal
Cagrilintide, a novel amylin analogue, shows promising body weight reducing effects.
Cagrilintide may be an effective treatment for weight loss, especially when combined with other therapies.
StrongSupportsmedium confidence
Cagrilintide, a novel amylin analogue suitable for once-weekly administration, has shown promising body weight reducing effects alone and in combination with the glucagon-like peptide 1 receptor agonist semaglutide.
Why this rating
Based on the mention of clinical development and effects.
Source
Long-acting amylin analogues for the management of obesity
David S. Mathiesen et al. · Current Opinion in Endocrinology Diabetes and Obesity · 2022
DOI 10.1097/med.0000000000000716
reviewCited 37×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →